ATE284885T1 - 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren - Google Patents

3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren

Info

Publication number
ATE284885T1
ATE284885T1 AT01974083T AT01974083T ATE284885T1 AT E284885 T1 ATE284885 T1 AT E284885T1 AT 01974083 T AT01974083 T AT 01974083T AT 01974083 T AT01974083 T AT 01974083T AT E284885 T1 ATE284885 T1 AT E284885T1
Authority
AT
Austria
Prior art keywords
pyrrol
indolyl
phenyl
glycogen synthase
synthase kinase
Prior art date
Application number
AT01974083T
Other languages
English (en)
Inventor
Leyi Gong
Andrew Grupe
Gary Allen Peltz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE284885T1 publication Critical patent/ATE284885T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01974083T 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren ATE284885T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27
PCT/EP2001/008293 WO2002010158A2 (en) 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta

Publications (1)

Publication Number Publication Date
ATE284885T1 true ATE284885T1 (de) 2005-01-15

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974083T ATE284885T1 (de) 2000-07-27 2001-07-18 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren

Country Status (32)

Country Link
US (2) US6479490B2 (de)
EP (1) EP1307447B1 (de)
JP (1) JP3984157B2 (de)
KR (1) KR20030017655A (de)
CN (1) CN1185229C (de)
AR (1) AR033989A1 (de)
AT (1) ATE284885T1 (de)
AU (1) AU2001293702A1 (de)
BR (1) BR0112965A (de)
CA (1) CA2417277A1 (de)
CZ (1) CZ2003555A3 (de)
DE (1) DE60107857T2 (de)
EC (1) ECSP034452A (de)
ES (1) ES2233691T3 (de)
GT (1) GT200100151A (de)
HK (1) HK1058670A1 (de)
HR (1) HRP20030030A2 (de)
HU (1) HUP0301431A2 (de)
IL (1) IL153851A0 (de)
JO (1) JO2293B1 (de)
MA (1) MA26936A1 (de)
MX (1) MXPA03000695A (de)
NO (1) NO20030328L (de)
NZ (1) NZ523462A (de)
PA (1) PA8523001A1 (de)
PE (1) PE20020338A1 (de)
PL (1) PL366701A1 (de)
RU (1) RU2003104796A (de)
UY (1) UY26857A1 (de)
WO (1) WO2002010158A2 (de)
YU (1) YU4403A (de)
ZA (1) ZA200300216B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224932A4 (de) * 1999-08-20 2002-10-16 Sagami Chem Res Wirkstoffe zur hemmung des zelltods
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
PE20020544A1 (es) * 2000-11-07 2002-07-30 Novartis Ag Derivados de indolilmaleimida
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
CA2461144A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
CN100409840C (zh) * 2002-01-10 2008-08-13 霍夫曼-拉罗奇有限公司 GSK-3β抑制剂在制备增加骨生成的药物中的应用
ES2276048T3 (es) 2002-03-05 2007-06-16 Eli Lilly And Company Derivados de purina como inhibidores de cinasa.
WO2003076398A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
EP1513520B1 (de) 2002-06-05 2008-09-24 Janssen Pharmaceutica N.V. Substituierte pyrroline als kinase inhibitoren
MXPA04012188A (es) 2002-06-05 2005-07-25 Johnson & Johnson Derivados de bisindolil-maleimida como inhibidores de cinasa.
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
JP2007509185A (ja) * 2003-10-27 2007-04-12 ノバルティス アクチエンゲゼルシャフト βアミロイド産生および/または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
AU2005239812B2 (en) * 2004-05-12 2011-04-14 Bayer Cropscience Ag Plant growth regulation
EP1819697B1 (de) 2004-12-08 2012-08-01 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimidderivate und ihre verwendung als angiogenese inhibitoren
JP4747364B2 (ja) * 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
EP1885454A2 (de) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Verwendung von gsk-3-hemmern zur prävention und behandlung von pankreatischen autoimmunkrankheiten
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
KR20110031355A (ko) * 2008-06-25 2011-03-25 엔비보 파마슈티칼즈, 인코퍼레이티드 1,2―이치환된 헤테로사이클릭 화합물
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (de) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren
JP5790348B2 (ja) * 2010-09-08 2015-10-07 住友化学株式会社 ピリダジノン化合物の製造法およびその製造中間体
EP2474541A1 (de) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (de) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458A (zh) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
JP2000502097A (ja) 1995-12-20 2000-02-22 メディカル、リサーチ、カウンシル タンパク質合成の制御、および作用薬のスクリーニング法
EP1019043A4 (de) 1996-05-07 2003-07-30 Univ Pennsylvania Inhibitoren der glykogensynthese-kinase 3 und verfahren zu ihrer identifizierung und verwendung
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
CN1444581A (zh) 2003-09-24
CA2417277A1 (en) 2002-02-07
WO2002010158A2 (en) 2002-02-07
UY26857A1 (es) 2002-01-31
NO20030328D0 (no) 2003-01-22
YU4403A (sh) 2006-05-25
MA26936A1 (fr) 2004-12-20
EP1307447B1 (de) 2004-12-15
DE60107857D1 (de) 2005-01-20
PL366701A1 (en) 2005-02-07
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
DE60107857T2 (de) 2005-12-08
CZ2003555A3 (en) 2004-03-17
WO2002010158A3 (en) 2002-05-16
CN1185229C (zh) 2005-01-19
KR20030017655A (ko) 2003-03-03
US6479490B2 (en) 2002-11-12
ZA200300216B (en) 2004-04-08
MXPA03000695A (es) 2003-06-04
PA8523001A1 (es) 2002-10-24
NO20030328L (no) 2003-01-22
JP3984157B2 (ja) 2007-10-03
HK1058670A1 (en) 2004-05-28
BR0112965A (pt) 2003-07-08
GT200100151A (es) 2002-05-23
JP2004505078A (ja) 2004-02-19
HRP20030030A2 (en) 2005-02-28
HUP0301431A2 (hu) 2003-08-28
AU2001293702A1 (en) 2002-02-13
PE20020338A1 (es) 2002-04-23
IL153851A0 (en) 2003-07-31
JO2293B1 (en) 2005-09-12
US20020052397A1 (en) 2002-05-02
US20020188018A1 (en) 2002-12-12
ES2233691T3 (es) 2005-06-16
EP1307447A2 (de) 2003-05-07
AR033989A1 (es) 2004-01-21
ECSP034452A (es) 2003-03-10

Similar Documents

Publication Publication Date Title
ATE284885T1 (de) 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
DE60117568D1 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
AP2005003383A0 (en) Aminoheteroaryl compounds as protein kinase inhibitors.
AP2332A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors.
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
DE60128709D1 (de) Triazol-verbindungen als protein-kinase-inhibitoren
DK1658292T3 (da) Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer
AP2326A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
HK1071572A1 (en) PyrazoloÄ1,5-AÜpyrimidine compounds as cyclin dependent kinase inhibitors
HUP0301181A2 (en) Imidazole derivatives as raf kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
PT1345922E (pt) Compostos de pirazole uteis como inibidores de proteina-quinase
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
IS8293A (is) Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
ZA200700159B (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties